Home > Oncology > ESMO 2020 > Gastrointestinal Cancers > Rechallenge of RAS/BRAF wildtype CRC with avelumab plus cetuximab

Rechallenge of RAS/BRAF wildtype CRC with avelumab plus cetuximab

Conference
ESMO 2020
First results of the CAVE trial showed encouraging effectiveness of rechallenging patients with RAS wildtype metastatic colorectal cancer (mCRC) in third line with cetuximab plus avelumab. Rechallenge strategies with anti-epidermal growth factor receptor (EGFR) drugs have been evaluated in patients with refractory RAS/BRAF wildtype mCRC after response to anti-EGFR based first-line therapy [1]. In the phase 2, single-arm CAVE mCRC trial, 77 patients with RAS wildtype mCRC at baseline were enrolled [2]. All patients were treated first-line with chemotherapy plus anti-EGFR, achieved a partial or complete response in first line, and received a second-line treatment without anti-EGFR. In third-line, patients were rechallenged with avelumab (10 mg/kg every 14 days) plus cetuximab (400 mg/m2 and subsequently 250 mg/m2 weekly) until progression of disease or unacceptable toxicity. Median overall survi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on